We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

By LabMedica International staff writers
Posted on 01 May 2025
Print article
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how light interacts with it, is a widely used technique in chemistry, materials science, and medicine. However, interpreting the resulting spectral data can be challenging and time-consuming, especially when the differences between samples are subtle. Now, a new machine learning (ML) algorithm has been developed to effectively interpret the "light signatures" or optical spectra of molecules, materials, and disease biomarkers, offering the potential for faster and more precise medical diagnoses and sample analysis.

The algorithm, known as Peak-Sensitive Elastic-net Logistic Regression (PSE-LR), was developed by researchers at Rice University (Houston, TX, USA) specifically to analyze light-based data. PSE-LR is not only capable of accurately classifying different samples but also offers transparency in its decision-making process, a feature that many advanced ML models typically lack. The algorithm provides a "feature importance map" that highlights the specific parts of the spectrum that contributed to a particular classification decision, making the results easier to interpret, verify, and act upon. In tests comparing PSE-LR to other ML models, it demonstrated superior performance, particularly in identifying subtle or overlapping spectral features.

The model also excelled in various real-world tests, including detecting ultralow concentrations of the SARS-CoV-2 spike protein in fluid samples, identifying neuroprotective solutions in mouse brain tissue, classifying Alzheimer’s disease samples, and differentiating between 2D semiconductors. This new algorithm could pave the way for the creation of novel diagnostics, biosensors, or nanodevices. The optical spectra of tissues or other biological samples can provide valuable insights into what is happening within the body. This capability is critical because quicker and more accurate disease detection can lead to improved treatments and potentially save lives. Beyond healthcare, the method can also aid scientists in better understanding new materials, facilitating the development of smarter biosensors and more effective nanodevices.

“Imagine being able to detect early signs of diseases like Alzheimer’s or COVID-19 just by shining a light on a drop of fluid or a tissue sample,” said Ziyang Wang, an electrical and computer engineering doctoral student at Rice who is a first author on a study published in ACS Nano. “Our work makes this possible by teaching computers how to better ‘read’ the signal of light scattered from tiny molecules.”

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
PSA Test
Humasis PSA Card
New
Creatine Kinase-MB Assay
CK-MB Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.